Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka; Elizabeth A. Daugherity; Amanda L. McCormick; Trevor S. Anderson; Savanna L. Smith; Caryn Lawrence; Duke Appiah; Devin B. Lowe

doi:10.1158/1535-7163.29760626

August 1, 2025

Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

The bispecific antibody targets pd-l1 and cd3 to enhance antitumor effects in colon cancer.
Colon cancer treatment showed improved protection with regorafenib and bispecific antibody in modeling studies.
Supplementary figure presents a model supporting the effectiveness of regorafenib in combination with the bispecific antibody.
Findings could impact treatment strategies in colon cancer, highlighting innovative approaches in cancer therapy.

Implication

Supplementary figure illustrates improved cancer protection after regorafenib and bispecific antibody treatment, suggesting beneficial effects in colon cancer.

Abstract

Supplementary Figure 8 provides a putative model for improved colon cancer protection after REG/bsAb sensitization

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0208 https://doi.org/10.1158/1535-7163.29760626

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 8 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading